• OPEN AN ACCOUNT
Indian Indices
Nifty
23,398.90 75.95
(0.33%)
Sensex
76,810.90 204.33
( 0.27%)
Bank Nifty
49,846.70 -48.40
( -0.10%)
Nifty IT
34,902.05 354.60
( 1.03%)
Global Indices
Nasdaq
17,608.44 264.89
(1.53%)
Dow Jones
38,712.21 -35.21
(-0.09%)
Hang Seng
18,112.63 174.79
(0.97%)
Nikkei 225
38,720.47 -156.24
(-0.40%)
Forex
USD-INR
83.56 0.05
(0.06%)
EUR-INR
89.81 -0.02
(-0.02%)
GBP-INR
106.39 0.17
(0.16%)
JPY-INR
0.53 0.00
(-0.07%)

EQUITY - MARKET SCREENER

Cipla Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
500087
INE059A01026
346.471431
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
CIPLA
33.49
124395.34
EPS(TTM)
Face Value()
Div & Yield %
46
2
0.55
 

Cipla receives USFDA approval for Lanreotide Injection
May 22,2024
Cipla USA Inc., wholly owned subsidiary of Cipla USA has received the final approval for its Abbreviated New Drug Application (ANDA) for Lanreotide Injection 120 mg/0.5 mL, 90 mg/0.3 mL, 60 mg/0.2 mL from USFDA.

Cipla's Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline® Depot (lanreotide) Injection and is indicated for the treatment of patients with Acromegaly and Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs).

The approval for the generic version of Lanreotide Acetate is in line with Cipla's growth strategy in the complex product segment and will strengthen Cipla's position in the US market.

According to IQVIA (IMS Health), Somatuline® Depot (Lanreotide) had US sales of approximately $898M for the 12-month period ending March 2024.